Shuttle Pharmaceuticals (NASDAQ:SHPH – Get Free Report) and Cassava Sciences (NASDAQ:FLNA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.
Analyst Ratings
This is a summary of current recommendations and price targets for Shuttle Pharmaceuticals and Cassava Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shuttle Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Cassava Sciences | 1 | 0 | 1 | 0 | 2.00 |
Cassava Sciences has a consensus target price of $5.00, suggesting a potential upside of 313.22%. Given Cassava Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Shuttle Pharmaceuticals.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shuttle Pharmaceuticals | N/A | N/A | -$11.72 million | ($4.77) | -0.79 |
| Cassava Sciences | N/A | N/A | -$90.97 million | ($1.61) | -0.75 |
Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Shuttle Pharmaceuticals has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.72, meaning that its stock price is 172% less volatile than the S&P 500.
Profitability
This table compares Shuttle Pharmaceuticals and Cassava Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shuttle Pharmaceuticals | N/A | -408.34% | -138.15% |
| Cassava Sciences | N/A | -53.90% | -34.20% |
Institutional and Insider Ownership
4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Cassava Sciences beats Shuttle Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
About Shuttle Pharmaceuticals
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.
About Cassava Sciences
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Receive News & Ratings for Shuttle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shuttle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
